ArthroCare Technologies Featured at ISAKOS.

ArthroCare Sports Medicine to Present Live Surgical Demonstration, Surgical Workshops and Series of Lectures at International Congress

AUSTIN, Texas -- ArthroCare([R]) Corp. (Nasdaq:ARTC) announced today that it will present a live surgical demonstration and collection of workshops and lectures from May 27 - 31 at this year's 6th Biennial ISAKOS Congress, in Florence, Italy.

Focused on advancing the worldwide exchange and dissemination of education, research and patient care in sports medicine and arthroscopy, the ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopedic Sports Medicine) Congress in its sixth year has fast become one of the preeminent gatherings of surgeons internationally.

Among the anticipated highlights of this year's Congress is the scheduled May 28th live surgical demonstration of ArthroCare's OPUS[R] System that makes minimally invasive labrum and rotator cuff repair a reality for almost any shoulder injury. The totally arthroscopic procedure, done through just a few small nicks in the skin, will be performed by John Uribe, MD of the University of Miami School of Medicine. Uribe will also be joined Wednesday May 30th by James Tasto, MD of San Diego, California; Mark Haber, MD of Australia; and Gunter Spahn, MD of Germany for a series of workshops on ArthroCare's innovative arthroscopic and radiofrequency technologies.

Among the topics being discussed at the Congress will be ArthroCare's Topaz Microdebrider; and new double row techniques for rotator cuff repair made possible by surgeons utilizing the company's Opus AutoCuff system.

Tasto, Spahn and Andre Weimann, MD of Germany will also be presenting a series of lectures throughout the week focused on ArthroCare technologies.

"It's rewarding to be given the opportunity to demonstrate the sound science and innovative processes behind our technologies at such a far-reaching event," said Jack Giroux, President of ArthroCare Sports Medicine. "One of the nice things about ISAKOS as a group is that they constantly seek out the latest breakthroughs specific to arthroscopic and sports medicine procedures and work to spread the word of these technologies on a global level. That our Opus and Topaz technologies are generating such interest at this year's event is a strong indication of just how special these technologies are."

About ArthroCare

Founded in 1993, ArthroCare Corp. (www.arthrocare.com) is a highly innovative, multi-business medical device company that develops, manufactures and markets minimally invasive surgical products. With these products, ArthroCare targets a multi-billion dollar market opportunity across several medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures. Many of ArthroCare's products are based on its patented Coblation technology, which uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue -- minimizing damage to healthy tissue. Used in more than four million surgeries worldwide, Coblation-based devices have been developed and marketed for sports medicine; spine/neurologic; ear, nose and throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of novel technologies to its portfolio, including Opus Medical sports medicine, Parallax spine and Applied Therapeutics ENT products, to complement Coblation within key indications.

Safe Harbor Statements

Except for historical information, this press release includes forward-looking statements. These statements include, but are not limited to, the company's stated business outlook for fiscal 2007, continued strength of the company's fundamental position, the strength of the company's technology, the company's belief that strategic moves will enhance achievement of the company's long term potential, the potential and expected rate of growth of new businesses, continued success of product diversification efforts, and other statements that involve risks and uncertainties. These risks and uncertainties include, but are not limited to the uncertainty of success of the company's non-arthroscopic products, competitive risk, uncertainty of the success of strategic business alliances, uncertainty over reimbursement, need for governmental clearances or approvals before selling products, the uncertainty of protecting the company's patent position, and any changes in financial results from completion of year-end audit activities. These and other risks and uncertainties are detailed from time to time in the company's Securities and Exchange Commission filings, including ArthroCare's Form 10-K for the year ended Dec. 31, 2006 and Form 10-Q for the quarter ended March 31, 2007. Forward-looking statements are indicated by words or phrases such as "anticipates," "estimates," "projects," "believes," "intends," "expects," and similar words and phrases. Actual results may differ materially from management expectations.